Email your news and story ideas to: [email protected]
India's legal block on drug-testing to be reviewed
The current block on the US$450m industry in India may be lifted in a few months as the government plans to make changes and clarifications to the existing tight rules.
The Indian government plans to review restricted drug-testing rules pepmiba
Sign up for our free daily newsletter
YOUR PRIVACY - PLEASE READ CAREFULLY DATA PROTECTION STATEMENT
Below we explain how we will communicate with you. We set out how we use your data in our Privacy Policy.
Global City Media, and its associated brands will use the lawful basis of legitimate interests to use
the
contact details you have supplied to contact you regarding our publications, events, training,
reader
research, and other relevant information. We will always give you the option to opt out of our
marketing.
By clicking submit, you confirm that you understand and accept the Terms & Conditions and Privacy Policy
The clampdown happened earlier this year when the Supreme Court, in response to numerous public interest lawsuits, suspended 157 clinical trials. Indian standards had been seen by some as being rather loose but the legal response has largely frozen what was becoming a boom sector for the country. Mahima Datla, MD of Biological E, the vaccine producer, said that the shutdown 'will kill drug development in India. Companies will do their studies elsewhere and it is the Indian consumer who will suffer'. Source: The Financial Times
